JS Innomed Holdings Ltd. has identified Heterocyclic compounds characterized as serine/threonine-protein kinase ULK1 and/or ULK2 inhibitors.

Plastech Pharmaceutical Technology Co. Ltd. has developed new fused tricyclic derivative acting as focal adhesion kinase (FAK) inhibitors.

Genechem Inc. has created conjugates comprising gemcitabine covalently linked to sialyllactose through a linker and reported to be useful for the treatment of cancer.

Medipol Ueniversitesi Zonguldak Buelent Ecevit University has patented new specific arylidene barbiturate derivatives reported to be useful for the treatment of cancer.

Shanghai Wennai Pharmaceutical Technology Co. Ltd. has described new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast and prostate cancer.

The U.S. Patent and Trademark Office has provided updated guidance on the question of patent subject matter eligibility for inventions that rely on artificial intelligence, stating that a patent claim that does little more than recite an abstract idea is not subject-matter eligible.

Chengdu Mfs Pharma Co. Ltd. has disclosed substituted phenol derivatives potentially useful as analgesics, sedatives, hypnotics and anesthetics.

A joint Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. patent details NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.

Work at Intra-Cellular Therapies Inc. has led to the identification of heterocycle fused gamma-carbolines characterized as 5-HT2A receptor ligands reported to be useful for the treatment of neurological disorders.

Apichope Bio Pharmaceutical Co. Ltd., Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have jointly patented tricyclic compounds acting as G-protein coupled receptor 84 (GPR84) antagonists.